Recent Updates — BNTC

Benitec Biopharma Inc. dismissed Baker Tilly US, LLP as its independent registered public accounting firm and appointed Ernst & Young LLP (EY) to serve in that capacity for the fiscal year ending June 30, 2027. The change was made following a routine governance review by the Audit Committee, with no disagreements on accounting principles or reportable events cited between the company and Baker Tilly. A prior material weakness regarding share-based compensation controls reported in the 2025 annual report was remediated as of June 30, 2026. Benitec Biopharma Inc. operates in the biotechnology industry, focusing on developing nucleic acid therapeutics for genetic diseases.

Benitec Biopharma Inc. reported full-year financial results for the fiscal year ended June 30, 2026, alongside an operational update on its lead candidate BB-301. The company incurred a net loss of $45.5 million, or $0.98 per share, compared to a $37.9 million loss in the prior year, driven by increased research and development expenses of $23.4 million and general and administrative costs of $27.8 million. As of June 30, 2026, Benitec held approximately $180 million in cash. Clinically, all six Cohort 1 patients completed the 12-month follow-up period for BB-301, while Cohort 2 is fully enrolled with three safely treated patients. The company held a Type C meeting with the FDA to discuss pivotal study design and anticipates initiating the pivotal trial in mid-2027. Benitec Biopharma Inc. operates as a clinical-stage biotechnology company developing disease-modifying genetic medicines using its proprietary ddRNAi platform.